Immunotherapy:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Ashland :
Delve Publishing,
2020.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | Potentiating Antitumor T Cells: Costimulation, Cytokines, and Microbial Signals. |
| Beschreibung: | 1 online resource (283 pages) |
| ISBN: | 1774078929 9781774078921 |
Internformat
MARC
| LEADER | 00000cam a2200000 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1231611112 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 210116s2020 xx o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d N$T |d OCLCF |d OCLCO |d K6U |d OCLCQ |d OCLCO |d OCLCL |d OCLCQ | ||
| 020 | |a 1774078929 | ||
| 020 | |a 9781774078921 |q (electronic bk.) | ||
| 035 | |a (OCoLC)1231611112 | ||
| 050 | 4 | |a RM275 | |
| 082 | 7 | |a 616.079 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Sripathi, Shiv Sanjeevi. | |
| 245 | 1 | 0 | |a Immunotherapy |
| 260 | |a Ashland : |b Delve Publishing, |c 2020. | ||
| 300 | |a 1 online resource (283 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Cover -- Copyright -- DECLARATION -- ABOUT THE EDITORS -- TABLE OF CONTENTS -- List of Contributors -- List of Abbreviations -- Preface -- Chapter 1 History of Immunotherapy -- 1.1 Introduction -- 1.2 Immune System -- 1.3 Therapies based on Anti-bodies -- 1.4 Immunosuppression and reduction in treatment -- 1.5 Cancer Vaccines -- 1.6 Using viruses to heal -- 1.7 Final points -- 1.8 References -- Chapter 2 Immunotherapy: Looking at the Details -- 2.1 The basics -- 2.2 Overview of Immunotherapy -- 2.3 Antibodies and Tumor-specific monoclonal antibodies (mAbs) -- 2.4 Cytokines for Treatment | |
| 505 | 8 | |a 2.5 Oncolytic Viruses -- 2.6 Dendritic Cells and Immunotherapy -- 2.7 PRR Agonists -- 2.8 Immune Checkpoint Inhibitors: -- 2.9 Vaccines -- 2.10 Adoptive Cell Transfer (ACT) Strategies -- 2.11 Other Approaches -- 2.12 Summary -- 2.13 References -- Chapter 3 Summarizing The Challenges and Solutions -- 3.1 Looking at Consistenc -- 3.2 Identification of Clinically Significant Biomarkers -- the Inherent Difficulties -- 3.3 Requirement for an Increased Number of Predictive Biomarkers -- 3.4 Efficacy being Impeded by Tumor Heterogeneity -- 3.5 Resistance to Drug Treatment -- Development | |
| 505 | 8 | |a 3.6 Efficacy Evaluation Needs Distinct Clinical Study Designs -- 3.7 Cancer Immunotherapy Drugs -- An Expensive Proposition -- 3.8 The Challenges and Solutions -- 3.9 The way Ahead -- 3.10 References -- Chapter 4 Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells -- Abstract -- Introduction -- Materials and Methods -- Results -- Discussion -- References -- Chapter 5 A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer -- Abstract -- Introduction -- Results -- Discussion -- Conclusion -- Methods -- References | |
| 505 | 8 | |a Chapter 6 Immunotherapy In Gastrointestinal Cancers -- Abstract -- Gastrointestinal Cancers: Where Do We Stand? -- The Rationale For Immunotherapy In Gi Cancers -- Immunotherapeutic Strategies: A General Overview -- Focus On Gastric, Esophageal, and Pancreatic Cancers -- Focus on Colorectal Cancer -- Focus on Hepatocellular Carcinoma -- Possible Biomarkers For Immunotherapy: The Pathologist Perspective -- Back To The Bench: Biomarkers And Genetic Signatures as Predictive Factors -- Future Perspectives -- References -- Chapter 7 Harnessing the Microbiome to Enhance Cancer Immunotherapy -- Abstract | |
| 505 | 8 | |a Introduction -- Coley's Toxin In Tumor Immunotherapy -- Commensal Microflora Regulates The Innate and Adaptive Immune System -- Toll-Like Receptors in Cancer Immunotherapy -- Tlr Expression on T Cells and Cancer Cells -- Vaccines Promote Weak T Cell-Mediated Tumor Regression -- Act Therapy: A Promising Cancer Treatment -- Lymphodepletion Augments Act Therapy -- Mechanisms Of Tbi Effectiveness: Sinks, Suppressors, and Microbial Activators -- Lymphodepletion Activates The Innate Immune System -- Mimicking Tbi: Promoting The Benefits While Removing The Harm | |
| 500 | |a Potentiating Antitumor T Cells: Costimulation, Cytokines, and Microbial Signals. | ||
| 650 | 0 | |a Immunotherapy. |0 http://id.loc.gov/authorities/subjects/sh85064592 | |
| 650 | 2 | |a Immunotherapy |0 https://id.nlm.nih.gov/mesh/D007167 | |
| 650 | 6 | |a Immunothérapie. | |
| 650 | 7 | |a Immunotherapy |2 fast | |
| 700 | 1 | |a Subramaniam, Raghu. | |
| 758 | |i has work: |a IMMUNOTHERAPY (Text) |1 https://id.oclc.org/worldcat/entity/E39PCYfXQwgfxdR4WCg7JhHYGd |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Sripathi, Shiv Sanjeevi. |t Immunotherapy: a review and update. |d Ashland : Delve Publishing, ©2020 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2725296 |3 Volltext |
| 936 | |a BATCHLOAD | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6453536 | ||
| 938 | |a EBSCOhost |b EBSC |n 2725296 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1231611112 |
|---|---|
| _version_ | 1816882536999026688 |
| adam_text | |
| any_adam_object | |
| author | Sripathi, Shiv Sanjeevi |
| author2 | Subramaniam, Raghu |
| author2_role | |
| author2_variant | r s rs |
| author_facet | Sripathi, Shiv Sanjeevi Subramaniam, Raghu |
| author_role | |
| author_sort | Sripathi, Shiv Sanjeevi |
| author_variant | s s s ss sss |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM275 |
| callnumber-raw | RM275 |
| callnumber-search | RM275 |
| callnumber-sort | RM 3275 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | Cover -- Copyright -- DECLARATION -- ABOUT THE EDITORS -- TABLE OF CONTENTS -- List of Contributors -- List of Abbreviations -- Preface -- Chapter 1 History of Immunotherapy -- 1.1 Introduction -- 1.2 Immune System -- 1.3 Therapies based on Anti-bodies -- 1.4 Immunosuppression and reduction in treatment -- 1.5 Cancer Vaccines -- 1.6 Using viruses to heal -- 1.7 Final points -- 1.8 References -- Chapter 2 Immunotherapy: Looking at the Details -- 2.1 The basics -- 2.2 Overview of Immunotherapy -- 2.3 Antibodies and Tumor-specific monoclonal antibodies (mAbs) -- 2.4 Cytokines for Treatment 2.5 Oncolytic Viruses -- 2.6 Dendritic Cells and Immunotherapy -- 2.7 PRR Agonists -- 2.8 Immune Checkpoint Inhibitors: -- 2.9 Vaccines -- 2.10 Adoptive Cell Transfer (ACT) Strategies -- 2.11 Other Approaches -- 2.12 Summary -- 2.13 References -- Chapter 3 Summarizing The Challenges and Solutions -- 3.1 Looking at Consistenc -- 3.2 Identification of Clinically Significant Biomarkers -- the Inherent Difficulties -- 3.3 Requirement for an Increased Number of Predictive Biomarkers -- 3.4 Efficacy being Impeded by Tumor Heterogeneity -- 3.5 Resistance to Drug Treatment -- Development 3.6 Efficacy Evaluation Needs Distinct Clinical Study Designs -- 3.7 Cancer Immunotherapy Drugs -- An Expensive Proposition -- 3.8 The Challenges and Solutions -- 3.9 The way Ahead -- 3.10 References -- Chapter 4 Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells -- Abstract -- Introduction -- Materials and Methods -- Results -- Discussion -- References -- Chapter 5 A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer -- Abstract -- Introduction -- Results -- Discussion -- Conclusion -- Methods -- References Chapter 6 Immunotherapy In Gastrointestinal Cancers -- Abstract -- Gastrointestinal Cancers: Where Do We Stand? -- The Rationale For Immunotherapy In Gi Cancers -- Immunotherapeutic Strategies: A General Overview -- Focus On Gastric, Esophageal, and Pancreatic Cancers -- Focus on Colorectal Cancer -- Focus on Hepatocellular Carcinoma -- Possible Biomarkers For Immunotherapy: The Pathologist Perspective -- Back To The Bench: Biomarkers And Genetic Signatures as Predictive Factors -- Future Perspectives -- References -- Chapter 7 Harnessing the Microbiome to Enhance Cancer Immunotherapy -- Abstract Introduction -- Coley's Toxin In Tumor Immunotherapy -- Commensal Microflora Regulates The Innate and Adaptive Immune System -- Toll-Like Receptors in Cancer Immunotherapy -- Tlr Expression on T Cells and Cancer Cells -- Vaccines Promote Weak T Cell-Mediated Tumor Regression -- Act Therapy: A Promising Cancer Treatment -- Lymphodepletion Augments Act Therapy -- Mechanisms Of Tbi Effectiveness: Sinks, Suppressors, and Microbial Activators -- Lymphodepletion Activates The Innate Immune System -- Mimicking Tbi: Promoting The Benefits While Removing The Harm |
| ctrlnum | (OCoLC)1231611112 |
| dewey-full | 616.079 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.079 |
| dewey-search | 616.079 |
| dewey-sort | 3616.079 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04690cam a2200493 4500</leader><controlfield tag="001">ZDB-4-EBA-on1231611112</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">210116s2020 xx o 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">EBLCP</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1774078929</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781774078921</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1231611112</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM275</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.079</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sripathi, Shiv Sanjeevi.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunotherapy</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Ashland :</subfield><subfield code="b">Delve Publishing,</subfield><subfield code="c">2020.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (283 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cover -- Copyright -- DECLARATION -- ABOUT THE EDITORS -- TABLE OF CONTENTS -- List of Contributors -- List of Abbreviations -- Preface -- Chapter 1 History of Immunotherapy -- 1.1 Introduction -- 1.2 Immune System -- 1.3 Therapies based on Anti-bodies -- 1.4 Immunosuppression and reduction in treatment -- 1.5 Cancer Vaccines -- 1.6 Using viruses to heal -- 1.7 Final points -- 1.8 References -- Chapter 2 Immunotherapy: Looking at the Details -- 2.1 The basics -- 2.2 Overview of Immunotherapy -- 2.3 Antibodies and Tumor-specific monoclonal antibodies (mAbs) -- 2.4 Cytokines for Treatment</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2.5 Oncolytic Viruses -- 2.6 Dendritic Cells and Immunotherapy -- 2.7 PRR Agonists -- 2.8 Immune Checkpoint Inhibitors: -- 2.9 Vaccines -- 2.10 Adoptive Cell Transfer (ACT) Strategies -- 2.11 Other Approaches -- 2.12 Summary -- 2.13 References -- Chapter 3 Summarizing The Challenges and Solutions -- 3.1 Looking at Consistenc -- 3.2 Identification of Clinically Significant Biomarkers -- the Inherent Difficulties -- 3.3 Requirement for an Increased Number of Predictive Biomarkers -- 3.4 Efficacy being Impeded by Tumor Heterogeneity -- 3.5 Resistance to Drug Treatment -- Development</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3.6 Efficacy Evaluation Needs Distinct Clinical Study Designs -- 3.7 Cancer Immunotherapy Drugs -- An Expensive Proposition -- 3.8 The Challenges and Solutions -- 3.9 The way Ahead -- 3.10 References -- Chapter 4 Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells -- Abstract -- Introduction -- Materials and Methods -- Results -- Discussion -- References -- Chapter 5 A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer -- Abstract -- Introduction -- Results -- Discussion -- Conclusion -- Methods -- References</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 6 Immunotherapy In Gastrointestinal Cancers -- Abstract -- Gastrointestinal Cancers: Where Do We Stand? -- The Rationale For Immunotherapy In Gi Cancers -- Immunotherapeutic Strategies: A General Overview -- Focus On Gastric, Esophageal, and Pancreatic Cancers -- Focus on Colorectal Cancer -- Focus on Hepatocellular Carcinoma -- Possible Biomarkers For Immunotherapy: The Pathologist Perspective -- Back To The Bench: Biomarkers And Genetic Signatures as Predictive Factors -- Future Perspectives -- References -- Chapter 7 Harnessing the Microbiome to Enhance Cancer Immunotherapy -- Abstract</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Introduction -- Coley's Toxin In Tumor Immunotherapy -- Commensal Microflora Regulates The Innate and Adaptive Immune System -- Toll-Like Receptors in Cancer Immunotherapy -- Tlr Expression on T Cells and Cancer Cells -- Vaccines Promote Weak T Cell-Mediated Tumor Regression -- Act Therapy: A Promising Cancer Treatment -- Lymphodepletion Augments Act Therapy -- Mechanisms Of Tbi Effectiveness: Sinks, Suppressors, and Microbial Activators -- Lymphodepletion Activates The Innate Immune System -- Mimicking Tbi: Promoting The Benefits While Removing The Harm</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Potentiating Antitumor T Cells: Costimulation, Cytokines, and Microbial Signals.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Immunotherapy.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85064592</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Immunotherapy</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D007167</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Immunothérapie.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Subramaniam, Raghu.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">IMMUNOTHERAPY (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCYfXQwgfxdR4WCg7JhHYGd</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Sripathi, Shiv Sanjeevi.</subfield><subfield code="t">Immunotherapy: a review and update.</subfield><subfield code="d">Ashland : Delve Publishing, ©2020</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2725296</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="936" ind1=" " ind2=" "><subfield code="a">BATCHLOAD</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL6453536</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">2725296</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1231611112 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:30:11Z |
| institution | BVB |
| isbn | 1774078929 9781774078921 |
| language | English |
| oclc_num | 1231611112 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (283 pages) |
| psigel | ZDB-4-EBA |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | Delve Publishing, |
| record_format | marc |
| spelling | Sripathi, Shiv Sanjeevi. Immunotherapy Ashland : Delve Publishing, 2020. 1 online resource (283 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Print version record. Cover -- Copyright -- DECLARATION -- ABOUT THE EDITORS -- TABLE OF CONTENTS -- List of Contributors -- List of Abbreviations -- Preface -- Chapter 1 History of Immunotherapy -- 1.1 Introduction -- 1.2 Immune System -- 1.3 Therapies based on Anti-bodies -- 1.4 Immunosuppression and reduction in treatment -- 1.5 Cancer Vaccines -- 1.6 Using viruses to heal -- 1.7 Final points -- 1.8 References -- Chapter 2 Immunotherapy: Looking at the Details -- 2.1 The basics -- 2.2 Overview of Immunotherapy -- 2.3 Antibodies and Tumor-specific monoclonal antibodies (mAbs) -- 2.4 Cytokines for Treatment 2.5 Oncolytic Viruses -- 2.6 Dendritic Cells and Immunotherapy -- 2.7 PRR Agonists -- 2.8 Immune Checkpoint Inhibitors: -- 2.9 Vaccines -- 2.10 Adoptive Cell Transfer (ACT) Strategies -- 2.11 Other Approaches -- 2.12 Summary -- 2.13 References -- Chapter 3 Summarizing The Challenges and Solutions -- 3.1 Looking at Consistenc -- 3.2 Identification of Clinically Significant Biomarkers -- the Inherent Difficulties -- 3.3 Requirement for an Increased Number of Predictive Biomarkers -- 3.4 Efficacy being Impeded by Tumor Heterogeneity -- 3.5 Resistance to Drug Treatment -- Development 3.6 Efficacy Evaluation Needs Distinct Clinical Study Designs -- 3.7 Cancer Immunotherapy Drugs -- An Expensive Proposition -- 3.8 The Challenges and Solutions -- 3.9 The way Ahead -- 3.10 References -- Chapter 4 Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells -- Abstract -- Introduction -- Materials and Methods -- Results -- Discussion -- References -- Chapter 5 A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer -- Abstract -- Introduction -- Results -- Discussion -- Conclusion -- Methods -- References Chapter 6 Immunotherapy In Gastrointestinal Cancers -- Abstract -- Gastrointestinal Cancers: Where Do We Stand? -- The Rationale For Immunotherapy In Gi Cancers -- Immunotherapeutic Strategies: A General Overview -- Focus On Gastric, Esophageal, and Pancreatic Cancers -- Focus on Colorectal Cancer -- Focus on Hepatocellular Carcinoma -- Possible Biomarkers For Immunotherapy: The Pathologist Perspective -- Back To The Bench: Biomarkers And Genetic Signatures as Predictive Factors -- Future Perspectives -- References -- Chapter 7 Harnessing the Microbiome to Enhance Cancer Immunotherapy -- Abstract Introduction -- Coley's Toxin In Tumor Immunotherapy -- Commensal Microflora Regulates The Innate and Adaptive Immune System -- Toll-Like Receptors in Cancer Immunotherapy -- Tlr Expression on T Cells and Cancer Cells -- Vaccines Promote Weak T Cell-Mediated Tumor Regression -- Act Therapy: A Promising Cancer Treatment -- Lymphodepletion Augments Act Therapy -- Mechanisms Of Tbi Effectiveness: Sinks, Suppressors, and Microbial Activators -- Lymphodepletion Activates The Innate Immune System -- Mimicking Tbi: Promoting The Benefits While Removing The Harm Potentiating Antitumor T Cells: Costimulation, Cytokines, and Microbial Signals. Immunotherapy. http://id.loc.gov/authorities/subjects/sh85064592 Immunotherapy https://id.nlm.nih.gov/mesh/D007167 Immunothérapie. Immunotherapy fast Subramaniam, Raghu. has work: IMMUNOTHERAPY (Text) https://id.oclc.org/worldcat/entity/E39PCYfXQwgfxdR4WCg7JhHYGd https://id.oclc.org/worldcat/ontology/hasWork Print version: Sripathi, Shiv Sanjeevi. Immunotherapy: a review and update. Ashland : Delve Publishing, ©2020 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2725296 Volltext |
| spellingShingle | Sripathi, Shiv Sanjeevi Immunotherapy Cover -- Copyright -- DECLARATION -- ABOUT THE EDITORS -- TABLE OF CONTENTS -- List of Contributors -- List of Abbreviations -- Preface -- Chapter 1 History of Immunotherapy -- 1.1 Introduction -- 1.2 Immune System -- 1.3 Therapies based on Anti-bodies -- 1.4 Immunosuppression and reduction in treatment -- 1.5 Cancer Vaccines -- 1.6 Using viruses to heal -- 1.7 Final points -- 1.8 References -- Chapter 2 Immunotherapy: Looking at the Details -- 2.1 The basics -- 2.2 Overview of Immunotherapy -- 2.3 Antibodies and Tumor-specific monoclonal antibodies (mAbs) -- 2.4 Cytokines for Treatment 2.5 Oncolytic Viruses -- 2.6 Dendritic Cells and Immunotherapy -- 2.7 PRR Agonists -- 2.8 Immune Checkpoint Inhibitors: -- 2.9 Vaccines -- 2.10 Adoptive Cell Transfer (ACT) Strategies -- 2.11 Other Approaches -- 2.12 Summary -- 2.13 References -- Chapter 3 Summarizing The Challenges and Solutions -- 3.1 Looking at Consistenc -- 3.2 Identification of Clinically Significant Biomarkers -- the Inherent Difficulties -- 3.3 Requirement for an Increased Number of Predictive Biomarkers -- 3.4 Efficacy being Impeded by Tumor Heterogeneity -- 3.5 Resistance to Drug Treatment -- Development 3.6 Efficacy Evaluation Needs Distinct Clinical Study Designs -- 3.7 Cancer Immunotherapy Drugs -- An Expensive Proposition -- 3.8 The Challenges and Solutions -- 3.9 The way Ahead -- 3.10 References -- Chapter 4 Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells -- Abstract -- Introduction -- Materials and Methods -- Results -- Discussion -- References -- Chapter 5 A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer -- Abstract -- Introduction -- Results -- Discussion -- Conclusion -- Methods -- References Chapter 6 Immunotherapy In Gastrointestinal Cancers -- Abstract -- Gastrointestinal Cancers: Where Do We Stand? -- The Rationale For Immunotherapy In Gi Cancers -- Immunotherapeutic Strategies: A General Overview -- Focus On Gastric, Esophageal, and Pancreatic Cancers -- Focus on Colorectal Cancer -- Focus on Hepatocellular Carcinoma -- Possible Biomarkers For Immunotherapy: The Pathologist Perspective -- Back To The Bench: Biomarkers And Genetic Signatures as Predictive Factors -- Future Perspectives -- References -- Chapter 7 Harnessing the Microbiome to Enhance Cancer Immunotherapy -- Abstract Introduction -- Coley's Toxin In Tumor Immunotherapy -- Commensal Microflora Regulates The Innate and Adaptive Immune System -- Toll-Like Receptors in Cancer Immunotherapy -- Tlr Expression on T Cells and Cancer Cells -- Vaccines Promote Weak T Cell-Mediated Tumor Regression -- Act Therapy: A Promising Cancer Treatment -- Lymphodepletion Augments Act Therapy -- Mechanisms Of Tbi Effectiveness: Sinks, Suppressors, and Microbial Activators -- Lymphodepletion Activates The Innate Immune System -- Mimicking Tbi: Promoting The Benefits While Removing The Harm Immunotherapy. http://id.loc.gov/authorities/subjects/sh85064592 Immunotherapy https://id.nlm.nih.gov/mesh/D007167 Immunothérapie. Immunotherapy fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85064592 https://id.nlm.nih.gov/mesh/D007167 |
| title | Immunotherapy |
| title_auth | Immunotherapy |
| title_exact_search | Immunotherapy |
| title_full | Immunotherapy |
| title_fullStr | Immunotherapy |
| title_full_unstemmed | Immunotherapy |
| title_short | Immunotherapy |
| title_sort | immunotherapy |
| topic | Immunotherapy. http://id.loc.gov/authorities/subjects/sh85064592 Immunotherapy https://id.nlm.nih.gov/mesh/D007167 Immunothérapie. Immunotherapy fast |
| topic_facet | Immunotherapy. Immunotherapy Immunothérapie. |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2725296 |
| work_keys_str_mv | AT sripathishivsanjeevi immunotherapy AT subramaniamraghu immunotherapy |